Eye fluid test may personalize uveitis treatment

NCT ID NCT07262437

Ongoing Knowledge-focused Sponsor: University of Milan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether analyzing fluid from the eye can predict which immunosuppressive drug will work best for people with non-infectious uveitis, an eye inflammation condition. About 220 participants who haven't responded well to steroids will provide eye fluid and blood samples. Researchers will measure immune signals in the fluid and compare them to how patients respond to standard drugs like methotrexate or adalimumab. The goal is to make treatment more personalized and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the right immunosuppressive drug for each uveitis patient, improving treatment outcomes.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anterior uveitis endophthalmitis Inflammation posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION EYE UVEITIS UVEITIS POSTERIOR NON-INFECTIOUS UVEITIS, ANTERIOR

Contacts and locations

Locations

ASST Fatebenefratelli Sacco P.O.L.Sacco

Milan, 20157, Italy
AUSL Reggio Emilia

Reggio Emilia, 42122, Italy
IRCCS San Raffaele Università Vita e Salute

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.